Comparing elranatamab with standard care for newly diagnosed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 69 years old.
- You have been diagnosed with multiple myeloma and are eligible for high-dose chemotherapy and an autologous stem cell transplant.
- You have not had any previous treatment for multiple myeloma (except a small amount of steroids).
- Your overall health is good (ECOG performance status 0, 1, or 2).
- Blood counts and organ function are within certain limits (your doctor will check these).
- You do not have other active cancers, uncontrolled infections, or significant heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
This trial compares two treatments for newly diagnosed multiple myeloma patients who are not eligible for or have delayed stem cell transplant. One group gets elranatamab plus a light version of RVd (lenalidomide, bortezomib, dexamethasone), and the other gets daratumumab plus the same light RVd. The goal is to find which combination works better.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial tests a combination of four drugs (elranatamab, isatuximab, bortezomib, and lenalidomide) for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this combination is safe and effective.
Hear when a new Multiple Myeloma, Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.